{
    "clinical_study": {
        "@rank": "102549", 
        "arm_group": [
            {
                "arm_group_label": "Levothyroxine", 
                "arm_group_type": "Experimental", 
                "description": "In the intervention arm patients will start levothyroxine therapy at 4 weeks after RAI therapy. The initial dose of levothyroxine will be 25 mcg/day. It will be increased to 50 mcg/day 2 weeks later and then adjusted at 8 weeks post RAI based on a full face-to-face clinical and biochemical evaluation."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "In the control arm patients will receive placebo capsules and be evaluated for levothyroxine therapy during a full face-to-face evaluation at 8 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The study will try to answer the question of whether early treatment with levothyroxine at 4\n      weeks after radioactive iodine for Graves'disease will prevent overt hypothyroidism (low\n      thyroid hormone levels)."
        }, 
        "brief_title": "Early Levothyroxine Post Radioactive Iodine", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Graves' Disease", 
        "condition_browse": {
            "mesh_term": [
                "Graves Disease", 
                "Hypothyroidism"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria target all adult patients (ages 18-70 years) with GD who will receive\n        RAI for treatment of GD. Patient with clinically manifest GO will be excluded from the\n        study. We will also exclude patients with recent (<1 yr.) history of arrhythmias or any\n        history of ventricular arrhythmias, those with preexistent cardiomyopathy, those with\n        malnutrition and those with psychiatric history that could get worse if patient remains\n        persistently hyperthyroid. Patients unlikely to return for the planned follow-up visits,\n        to comply with the blood drawing schedule and with the completion of the hypothyroid-HDQL\n        and TQS questionnaires will also be excluded."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01950260", 
            "org_study_id": "13-002570"
        }, 
        "intervention": {
            "arm_group_label": "Levothyroxine", 
            "description": "Early initiation of levothyroxine after radioactive iodine (to start at 4 weeks).", 
            "intervention_name": "Levothyroxine", 
            "intervention_type": "Drug", 
            "other_name": "Thyroid hormone"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Iodine", 
                "Cadexomer iodine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Graves' disease", 
            "Radioactive iodine", 
            "Hypothyroidism"
        ], 
        "lastchanged_date": "March 31, 2014", 
        "location": {
            "contact": {
                "email": "Giesler.Paula@mayo.edu", 
                "last_name": "Paula Giesler, RN", 
                "phone": "507-255-8345"
            }, 
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905"
                }, 
                "name": "Mayo Clinic in Rochester"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Prevention of Overt Hypothyroidism Following Radioactive Iodine Therapy for Graves' Disease", 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Marius Stan, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Incidence of overt hypothyroidism at 8 weeks post RAI (TSH > 3.0 mIU/L or fT4 < 0.8 ng/dL)", 
            "measure": "Prevention of overt hypothyroidism", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01950260"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Marius Stan", 
            "investigator_title": "Assistant Professor of Medicine, Endocrinology Consultant", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Quality of Life measured by the hypothyroid-HRQL and the TSQ at 8 weeks and 6 months", 
            "measure": "Quality of Life", 
            "safety_issue": "No", 
            "time_frame": "8 weeks and 6 months"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}